文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

头孢地尔对比标准治疗医疗保健相关及医院获得性革兰阴性菌血流感染的研究者驱动随机对照试验:GAME CHANGER试验研究方案

Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
PubMed 文献 · Trials · 2021-12-07

GAME CHANGER是一项多中心、开放标签、非劣效性随机对照试验,比较头孢地尔与根据治疗临床医生选择的标准治疗抗生素方案在医疗保健相关或医院获得性革兰阴性菌血流感染成人住院患者中的疗效。计划在至少10个国家20个中心随机分配至少284例患者,按1:1接受头孢地尔或标准治疗5-14天,主要基于14天全因死亡率10%、非劣效界值10%估算样本量。

要点

  • 头孢地尔是新型铁载体头孢菌素,体外对碳青霉烯耐药肠杆菌目及多重耐药铜绿假单胞菌和鲍曼不动杆菌有强效活性。
  • 试验针对医疗保健相关或医院获得性革兰阴性菌血流感染成人住院患者,按1:1随机接受头孢地尔或标准治疗5-14天。
  • 样本量基于对照组14天全因死亡率10%、非劣效界值10%估算,至少需284例,把握度80%、双侧α=0.05。

核心结论

  • 随着抗菌药物耐药性增加,需要开发对革兰阴性病原体具有广谱活性的新抗生素如头孢地尔;通过选择有多重耐药病原体风险的人群并在临床病程早期(索引血培养48小时内)开始研究治疗,试验希望为临床医生提供该新型药物疗效的指导。

研究设计与样本

  • 多中心、开放标签、非劣效性随机对照试验,比较头孢地尔与标准治疗抗生素方案。
  • 纳入基于血培养阳性诊断为革兰阴性菌血流感染且获得方式符合医疗保健相关或医院获得性定义的成人住院患者。
  • 合格参与者按1:1随机分配至头孢地尔或标准治疗,接受5-14天抗生素治疗。
  • 试验招募将在至少10个国家(澳大利亚、马来西亚、新加坡、泰国、土耳其和希腊)的至少20个中心进行。
  • 样本量基于对照组估计14天全因死亡率10%、两组非劣效界值10%差异推算,至少需284例患者以达到80%把握度、双侧α=0.05。

主要发现

  • 头孢地尔在体外已被证明对广泛的革兰阴性菌具有强效活性,包括碳青霉烯耐药肠杆菌目(CRE)以及多重耐药(MDR)铜绿假单胞菌和鲍曼不动杆菌。
  • 近期临床数据显示头孢地尔在复杂性尿路感染和医院获得性肺炎中有效,但尚未作为血流感染治疗进行研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing rates of antibiotic resistance in Gram-negative organisms due to the presence of extended-spectrum beta-lactamases (ESBL), hyperproduction of AmpC enzymes, carbapenemases and other mechanisms of resistance are identified in common hospital- and healthcare-associated pathogens including Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii. Cefiderocol is a novel siderophore cephalosporin antibiotic with a catechol moiety on the 3-position side chain. Cefiderocol has been shown to be potent in vitro against a broad range of Gram-negative organisms, including carbapenem-resistant Enterobacteriaceae (CRE) and multi-drug-resistant (MDR) P. aeruginosa and A. baumannii. Recent clinical data has shown cefiderocol to be effective in the setting of complicated urinary tract infections and nosocomial pneumonia, but it has not yet been studied as treatment of bloodstream infection. METHODS: This study will use a multicentre, open-label non-inferiority trial design comparing cefiderocol and standard of care antibiotics. Eligible participants will be adult inpatients who are diagnosed with a bloodstream infection with a Gram-negative organism on the basis of a positive blood culture result where the acquisition meets the definition for healthcare-associated or hospital-acquired. It will compare cefiderocol with the current standard of care (SOC) antibiotic regimen according to the patient's treating clinician. Eligible participants will be randomised 1:1 to cefiderocol or SOC and receive 5-14 days of antibiotic therapy. Trial recruitment will occur in at least 20 sites in ten countries (Australia, Malaysia, Singapore, Thailand, Turkey and Greece). The sample size has been derived from an estimated 14 day, all-cause mortality rate of 10% in the control group, and a non-inferiority margin of 10% difference in the two groups. A minimum of 284 patients are required in total to achieve 80% power with a two-sided alpha level of 0.05. Data describing demographic information, risk factors, concomitant antibiotics, illness scores, microbiology, multidrug-resistant organism screening, discharge and mortality will be collected. DISCUSSION: With increasing antimicrobial resistance, there is a need for the development of new antibiotics with broad activity against Gram-negative pathogens such as cefiderocol. By selecting a population at risk for multi-drug-resistant pathogens and commencing study treatment early in the clinical illness (within 48 h of index blood culture) the trial hopes to provide guidance to clinicians of the efficacy of this novel agent. TRIAL REGISTRATION: The GAME CHANGER trial is registered under the US National Institute of Health ClinicalTrials.gov register, reference number NCT03869437 . Registered on March 11, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wright H, Harris PNA, Chatfield MD, et al. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Trials. 2021. PMID: 34876196. doi:10.1186/s13063-021-05870-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。